Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
87 Leser
Artikel bewerten:
(0)

Pacific Health Care Organization, Inc. Reports its Second Quarter 2024 Results

Irvine, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the "Company") (OTCQB: PFHO) yesterday filed with the Securities and Exchange Commission (the "Commission") its quarterly report on Form 10-Q announcing financial results for the quarter ended June 30, 2024.

Quarterly Results

The Company reported total revenue of $1,569,954 for the quarter ended June 30, 2024, compared with total revenue of $1,324,053 for the quarter ended June 30, 2023.

The Company reported income from operations of $191,995 for the quarter ended June 30, 2024, compared to income from operations of $145,118 during the quarter ended June 30, 2023.

The Company realized net income of $215,556 or $0.02 per share on a basic and fully diluted basis for the second quarter of 2024, compared to net income of $176,427 or $0.01 per share on a basic and fully diluted basis, for the second quarter of 2023.

For the six months ended June 30, 2024, net cash provided by operating activities was $249,563, whereas for the six months ended June 30, 2023, net cash provided by operating activities was $266,778. Net cash used in investing activities during the six months ended June 30, 2024, was $181,963 compared to net cash provided by investing activities of $1,103,981 during the six months ended June 30, 2023.

During the six months ended June 30, 2024, net cash used in financing activities was $14,155, which was the amount paid during the first quarter of 2024 of the remaining dividends payable from the Company's June 2023 one-time cash dividend of the $1,281,600. The remaining amount payable for the dividend as of June 30, 2024, is $57,858. During the six months ended June 30, 2023, net cash used in financing activities was $1,110,984.

The Company's cash balance at June 30, 2024 and December 31, 2023, was $2,619,437 and $2,565,992, respectively.

To better understand the Company's financial results, readers should review the Company's quarterly report on Form 10-Q.

About Pacific Health Care Organization, Inc.

The Company specializes in workers' compensation cost containment. The Company's business objective is to deliver value to its clients that reduces their workers' compensation related medical claims expense in a manner that will assure that injured employees receive high quality healthcare that allows them to recover from injury and return to gainful employment without undue delay. Workers' compensation costs continue to increase due to rising medical costs, inflation, fraud, and other factors. Medical and indemnity costs associated with workers' compensation in the state of California, where the Company maintains its principal operations, are billions of dollars annually. Through its wholly owned subsidiaries, the Company provides a range of effective workers' compensation cost containment services, including but not limited to, Health Care Organizations, Medical Provider Networks, utilization review, medical bill review, medical case management, employee advocate, workers' compensation carve-outs, and Medicare set-aside services. We also provide expert witness testimony, ancillary to our other services. We offer our services as a bundled solution, as standalone services, or as add-on services.

"Safe Harbor" Statement: Statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. Forward-looking statements are based on management's current judgment, expectations, estimates, projections, and assumptions about future events. While management believes these assumptions are reasonable, such statements are not guarantees of future results and involve certain risks and uncertainties which are difficult to predict. Therefore, actual results and trends may differ materially from what is forecast in any forward-looking statement due to a variety of factors. Additional information regarding these factors, such as the potential loss of one or more key customers on our business and results of operations, is contained in the Company's filings with the Commission, including without limitation, its annual reports on Form 10-K and its quarterly reports on Form 10-Q.

All forward-looking statements speak only as of the date they were made. The Company does not undertake any obligation to update or publicly release any revisions to any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.

To view the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the Commission yesterday and the Company's annual, quarterly and current reports and other information the Company files with the U.S. Securities and Exchange Commission go to: http://www.sec.gov. You may also view our annual report on Form 10-K and our quarterly reports on Form 10-Q on our website at http://www.pacifichealthcareorganization.com.


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.